A Phase 2/3 interventional study of Ketorolac Tromethamine 30 MG/ML Prefilled Syringe and Gabapentin in Pain, Postoperative and Osteoarthritis, Knee, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-01.
Sponsored by Assiut University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing Ketorolac Tromethamine in Pain, Postoperative — 3 open to participants now, 3 under way, 1 of them phase 3. Ketorolac Tromethamine · Pain, Postoperative.
Among the 23 studies testing Ketorolac Tromethamine in Pain, Postoperative, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 2/3, and was the 23rd registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →3 of the 23 studies testing Ketorolac Tromethamine in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Shady Grove Fertility Reproductive Science Center · Sites in United States
Ages 18–45 · Women only
By country, each count listing its studies:
Ketorolac Tromethamine: first FDA approval 1989 (TORADOL), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 6 · Phase 4 6
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 80 across the 23 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
109 studies in Pain, Postoperative by Assiut University: 31 open now, 32 under way, 5 of them phase 3. Of 49 finished, 0 (0%) have results posted.
Among the 109 studies in Pain, Postoperative by Assiut University, this one is the 37th largest by planned enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 in phase 2/3, reaches primary completion later than 17 of the 31 other live ones, and was the 90th registered.
Assiut University’s Pain, Postoperative studies by the year they started, since 2013.
2 of the studies testing Ketorolac Tromethamine in Pain, Postoperative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07047040Phase 3Assiut UniversityAnalgesic Efficacy of Pre-operative Dose of Ketorolac and Gabapentin | 2027-10-30 |
| NCT06158620University of Texas Southwestern Medical CenterIntra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing Ketorolac Tromethamine in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Assiut University’s 109 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
Evaluation of the analgesic efficacy of a pre-operative dose of ketorolac and gabapentin in reducing post-operative pain scores in patients undergoing TKA
Elective total knee arthroplasty (TKA) is the gold standard for management of arthritis-associated pain and disability in osteoarthritis patients who have failed non-operative treatment modalitiesFollowing TKA, patients experience severe pain mediated by multiple pathways Painful stimuli to the body are detected by the free endings of peripheral nerves called nociceptors. Pre-emptive analgesia is analgesia given before the onset of painful stimuli to prevent central sensitization of nervous system to subsequent stimuli that could increase pain Studies have shown that pre-emptive analgesia reduce immediate postoperative pain and also prevent the development of chronic pain by decreasing altered sensory processing . Multimodal analgesia is the rational approach to pain management since no single analgesia targets all types of pain Multimodal analgesia, which is the use of at least 2 agents with differing mechanisms for pain control, has been shown to reduce hospital length of stay by 1.2 days and rehabilitation length of stay by 10 to 13 days compared with traditional postoperative analgesia. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). It is a cost-effective non selective cox inhibitor it inhibits prostaglandin biosynthesis. It is a potent analgesic with moderate anti-inflammatory.it inhibits platelet aggregation and increases bleeding time GABA analogues like Gabapentin is a structural analogue of gamma amino butyric acid, which was introduced in 1994 as an antiepileptic drug, particularly for partial seizures These drugs supress the hyper excitability of dorsal horn neurons caused due to tissue damage. They are also known to bind to the alpha 2 - delta subunit of voltage gated calcium channels and they have anxiolytic effect In this study we will assess the analgesic efficacy of pre-operative dose of combined ketorolac and Gabapentin in patients undergoing TKA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Experimental group will receive single dose of gabapentin 800 mg capsule and ketorolac 30 mg Ampule, one hour prior to administration of spinal anesthesia
Drug: Ketorolac Tromethamine 30 MG/ML Prefilled Syringe · Drug: Gabapentin
control group will receive normal saline ampule and empty capsule one hour prior to administration of spinal anesthesia
Drug: Empty Medication Capsules
Drug page: Ketorolac TromethamineStudies of Ketorolac TromethamineKetorolac Tromethamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
two empty capsules of gabapentin
evaluate the analgesic efficacy of a pre-operative dose of ketorolac and gabapentin in reducing post-operative pain scores in patients undergoing TKA.
asses pain postoperatively at 6,12,24 hours using VAS score
Time frame: during the first 24 hours post-operatively
assess the impact of pre-operative ketorolac and gabapentin on post-operative opioid consumption
by recording the total amount of opioids in both groups and comparing them
Time frame: during the first 24 hours post-operatively
investigate the safety profile of pre-operative ketorolac and gabapentin
by recording any side effects of these drugs during the study
Time frame: during the first 24 hours post-operatively
evaluate the effect of pre-operative ketorolac and gabapentin on functional recovery
by using Time UP and Go(TUG) Test in both groups and comparing them
Time frame: during the month after surgery
Plan to share: No
Start is estimated for Aug 2025; primary completion for Oct 2027, 26 months later.
Of 49 non-industry phase 2/3 interventional studies under Pain, Postoperative, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 26 months is above that.
Counting every sponsor, half of 52 studies reached it within 17 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketorolac Tromethamine · Gabapentin